Trial Profile
A phase II, open label, multicenter study to assess the safety and efficacy of 100mg DPC 083 once daily in combination with nucleoside analogue reverse transcriptase inhibitors in HIV-1-infected subjects who are failing treatment with a non-nucleoside reverse transcriptase inhibitor-containing regimen
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Oct 2009
Price :
$35
*
At a glance
- Drugs DPC 083 (Primary) ; Nucleoside reverse transcriptase inhibitors
- Indications HIV-1 infections
- Focus Therapeutic Use
- 19 Oct 2005 New trial record.